Lower PHQ-9 • Lower GAD-7 • Reduce benzodiazepine & SSRI dose-escalation
Most Insurances Accepted
HIPAA-Secure Video Visits
Most Insurances Accepted
HIPAA-Secure Video Visits
CBT-certified physicians & NPs sync with your pharmacologic strategy and guide safe med tapering when appropriate.
Avg. –9 PHQ-9, –8 GAD-7, –35% benzodiazepine usage at 8 weeks.
Modules dismantle negative self-talk, catastrophizing, and teach evidence-based relaxation drills.
Evening / lunchtime slots provide convenient options for patients.
| Driver / Symptom | Core CBT-I Intervention |
Typical win
|
|---|---|---|
| Low mood / anhedonia | Behavioral activation & values-based scheduling | ↑ daily positive-activity count |
| Rumination & negative thoughts | Cognitive restructuring & thought-record drills | ↓ PHQ-9 by ≥ 5 pts |
| Excessive worry / GAD | Worry-time, probability re-estimation | ↓ GAD-7 by ≥ 5 pts |
| Panic symptoms | Interoceptive exposure & breathing retraining | ↓ panic-attack frequency |
| Sleep-related anxiety | CBT-I mini-module | +15% sleep efficiency |
| High benzo or PRN use | Taper ladder + coping skills | –35% benzo dosage |
PHQ-9 19, GAD-7 17, using clonazepam 4 ×/wk
Behavioral activation, cognitive reframing, graded exposure, benzo taper ladder
PHQ-9 9 (–10 pts), GAD-7 7 (–10 pts), clonazepam 1 ×/wk only; resumed weekly basketball with friends
Email: refer@mindbodycbt.com
Provider Line: (410) 449-4009